Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 19/20 | 0.51 |
| ▸ | ACLY | P53396 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2035210 | 0.89 | ACLY (0.50) | HTR6ACLYHTR2CADRA2A | |
| SCHEMBL12585078 | 0.81 | HTR6 (0.51) | HTR6ACLYHTR2CADRA2A | |
| SCHEMBL12585096 | 0.79 | ACLY (0.50) | HTR6ACLYHTR2CADRA2A | |
| SCHEMBL1422202 | 0.75 | HTR6 (0.57) | HTR6HTR2CADRA2A | |
| SCHEMBL1422650 | 0.75 | HTR6 (0.62) | HTR6HTR2C | |
| SCHEMBL1421968 | 0.75 | HTR6 (0.67) | HTR6HTR2C | |
| SCHEMBL1885156 | 0.74 | HTR6 (0.57) | HTR6HTR2CADRA2A | |
| SCHEMBL1422226 | 0.73 | HTR6 (0.57) | HTR6HTR2CADRA2A | |
| SCHEMBL1423386 | 0.73 | HTR6 (0.58) | HTR6HTR2CADRA2A | |
| SCHEMBL12659641 | 0.73 | HTR6 (0.56) | HTR6HTR2CADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968567-B2 | Compounds for the modulation of PPARγ activity | AMGEN INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100113522-A1 | COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY | AMGEN INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20060264481-A1 | Therapeutic modulation of PPARgamma activity | AMGEN INC. (US) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264481-A1 | Therapeutic modulation of PPARgamma activity | PPARG, PPARA, PPARD | HTR6 2600/4885ACLY 1810/4885HTR2C 3448/4885 |
| US-20100113522-A1 | COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY | PPARG, PPARA, PPARD | HTR6 1724/4885ACLY 730/4885HTR2C 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.